Intra-Cellular Therapies Q3 2023 Earnings Report $83.45 -0.69 (-0.82%) (As of 12/20/2024 05:31 PM ET) Earnings HistoryForecast Intra-Cellular Therapies EPS ResultsActual EPS-$0.25Consensus EPS -$0.59Beat/MissBeat by +$0.34One Year Ago EPSN/AIntra-Cellular Therapies Revenue ResultsActual Revenue$126.17 millionExpected Revenue$118.35 millionBeat/MissBeat by +$7.82 millionYoY Revenue GrowthN/AIntra-Cellular Therapies Announcement DetailsQuarterQ3 2023Date11/2/2023TimeN/AConference Call ResourcesPress ReleaseITCI Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by This Crypto Is Set to Explode in December (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Intra-Cellular Therapies Earnings HeadlinesIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives Consensus Rating of "Moderate Buy" from BrokeragesDecember 20 at 3:45 AM | americanbankingnews.comIntra-Cellular presents data from CAPLYTA adjunctive MDD Phase 3 programDecember 11, 2024 | markets.businessinsider.comThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…December 21, 2024 | Crypto 101 Media (Ad)Intra-Cellular Therapies Inc (ITCI) Presents Promising Data on CAPLYTA for Major Depressive DisorderDecember 11, 2024 | gurufocus.comIntra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual MeetingDecember 11, 2024 | globenewswire.comIntra-Cellular recently submitted a sNDA to the U.S. FDA for CAPLYTA for MDDDecember 3, 2024 | markets.businessinsider.comSee More Intra-Cellular Therapies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Intra-Cellular Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Intra-Cellular Therapies and other key companies, straight to your email. Email Address About Intra-Cellular TherapiesIntra-Cellular Therapies (NASDAQ:ITCI), a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.View Intra-Cellular Therapies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
